Amylyx Pharmaceuticals (AMLX) Competitors $8.24 -0.06 (-0.69%) As of 02:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. CRNX, MOR, ALVO, RXRX, MIRM, CPRX, NAMS, GMTX, RARE, and AMRXShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. Its Competitors Crinetics Pharmaceuticals MorphoSys Alvotech Recursion Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals NewAmsterdam Pharma Gemini Therapeutics Ultragenyx Pharmaceutical Amneal Pharmaceuticals Crinetics Pharmaceuticals (NASDAQ:CRNX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Is CRNX or AMLX more profitable? Crinetics Pharmaceuticals' return on equity of -30.95% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -30.95% -28.12% Amylyx Pharmaceuticals N/A -77.21%-63.84% Do analysts recommend CRNX or AMLX? Crinetics Pharmaceuticals currently has a consensus price target of $69.50, indicating a potential upside of 125.51%. Amylyx Pharmaceuticals has a consensus price target of $11.75, indicating a potential upside of 42.55%. Given Crinetics Pharmaceuticals' higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, CRNX or AMLX? Crinetics Pharmaceuticals has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M2,774.60-$298.41M-$3.82-8.07Amylyx Pharmaceuticals$87.37M8.41-$301.74M-$3.11-2.65 Do institutionals & insiders believe in CRNX or AMLX? 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, CRNX or AMLX? Crinetics Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500. Does the media prefer CRNX or AMLX? In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 8 mentions for Crinetics Pharmaceuticals and 5 mentions for Amylyx Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.48 beat Amylyx Pharmaceuticals' score of 0.95 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCrinetics Pharmaceuticals beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$735.49M$2.76B$5.71B$9.51BDividend YieldN/A1.78%4.60%3.99%P/E Ratio-2.659.0628.0720.02Price / Sales8.41744.11459.47103.02Price / CashN/A166.2336.5558.97Price / Book3.435.188.615.88Net Income-$301.74M$30.99M$3.24B$258.50M7 Day Performance-1.16%7.26%3.83%2.03%1 Month Performance31.68%15.66%10.40%12.52%1 Year Performance329.32%-1.06%34.13%19.07% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals3.309 of 5 stars$8.24-0.7%$11.75+42.5%+332.3%$735.49M$87.37M-2.65200CRNXCrinetics Pharmaceuticals3.6781 of 5 stars$30.95-0.5%$69.50+124.6%-43.1%$2.90B$1.04M-8.10210Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech2.8352 of 5 stars$8.64+0.1%$16.00+85.2%-21.0%$2.60B$491.98M23.351,032RXRXRecursion Pharmaceuticals1.4367 of 5 stars$6.40+9.6%$7.00+9.4%-19.8%$2.60B$58.84M-3.62400High Trading VolumeMIRMMirum Pharmaceuticals3.8551 of 5 stars$51.95+0.0%$65.50+26.1%+33.5%$2.57B$336.89M-32.27140Positive NewsCPRXCatalyst Pharmaceuticals4.9232 of 5 stars$21.01-0.1%$32.83+56.3%+20.0%$2.56B$491.73M13.3880News CoveragePositive NewsAnalyst RevisionNAMSNewAmsterdam Pharma3.7852 of 5 stars$22.56+1.6%$41.30+83.1%+23.8%$2.53B$45.56M-12.004GMTXGemini TherapeuticsN/A$57.770.0%N/A+32.1%$2.50BN/A-57.7730High Trading VolumeRAREUltragenyx Pharmaceutical4.35 of 5 stars$26.39+0.3%$83.64+216.9%-39.5%$2.49B$560.23M-4.491,294Upcoming EarningsGap DownHigh Trading VolumeAMRXAmneal Pharmaceuticals3.1369 of 5 stars$7.91-0.8%$11.60+46.6%+8.0%$2.48B$2.79B-197.708,100 Related Companies and Tools Related Companies Crinetics Pharmaceuticals Competitors MorphoSys Competitors Alvotech Competitors Recursion Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Gemini Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Amneal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMLX Stock Alerts